Method of reliable determination of minimal lethal antibiotic concentrations.
about
In vitro antimicrobial activity of tigemonam, a new orally administered monobactamTigemonam, an oral monobactamIn vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolonePharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionMICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosisComparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosisComparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosisPotent synergism of the combination of fluconazole and cyclosporine in Candida albicansIn vitro activity of PD 127,391, an enhanced-spectrum quinoloneEfficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureusIn vitro activities of two glycylcyclinesFusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureusIn vitro activity of BAY 12-8039, a new fluoroquinoloneSusceptibility of Shigella species to erythromycin.Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbitsBactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.Development of a novel antimicrobial peptide, AG-30, with angiogenic properties.In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureusCritical importance of in vivo amoxicillin and cefotaxime concentrations for synergy in treatment of experimental Enterococcus faecalis endocarditis.Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.Evaluation of endpoints for antifungal susceptibility determinations with LY303366.Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.BRL-36650: in vitro studies and assessment of serum bactericidal activity after single-dose administration in volunteers.Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacinComparative in vitro antibiotic resistance of surface-colonizing coagulase-negative staphylococci.Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.In vitro activity of SK&F 104662, a new glycopeptide antibiotic.In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci.Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infectionInfluence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureusEvaluation of voriconazole pharmacodynamics using time-kill methodologyActivities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis.Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infectionCefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
P2860
Q24673656-164FEA24-B9F5-434B-8E44-1D63D6F7EDFDQ24674177-14ECA457-04CA-49F0-95D3-871F809191D7Q28326997-D3CB2CFA-2584-4DE8-8C9B-6463D71395DAQ28328534-FE6FD695-F181-4EE1-8D68-0FA81F276FF7Q28329425-680F1FF6-DDD6-46DC-A313-C5BDA447967DQ28333261-C3A35CC9-E2FA-468F-8A40-072F167DF0B7Q28340239-BBD21A46-8A9C-495C-81A7-CE143716E523Q28344597-7CD9EA85-F499-46AF-ADB8-2971861A745BQ28361070-E56AD181-82AC-4D5A-9B41-119C7E51A605Q28361126-AAB4A069-30CA-41D6-8968-E833837D0BD9Q28369373-5B53A7FD-84D2-4CF9-93E0-93340E41FB22Q28378451-FC38F3BB-8B2C-4F9D-A08F-4C51DBF2DFB0Q28379381-83732DC0-267B-4017-8039-6C681C17BEA5Q30451369-E22443E0-D85E-408C-8321-507DC8163E8AQ30451719-21585963-14A4-45EE-8F9B-68EA28B66EBDQ30451758-52F7402D-3207-427E-BE0C-8DA8E6F6F143Q33328109-3AE95EC2-CC95-4BDA-A002-F33EABA7FFD4Q33556476-FB8C09BB-6966-4F2C-8A45-277A5ADD5EB3Q33690243-768545D8-A8E3-416C-B307-D210E81A1A62Q33693370-19701DF0-3657-4BDB-9D55-E24C1C2CE66BQ33693384-E3047603-BD6D-48E8-88E1-F08264678A77Q33695704-49CEFB17-A420-4674-8FD8-22D5E235FEABQ33738474-D93058D6-DEAA-41BE-A5F3-4BAA0B295C20Q33739836-5A4268E4-286E-4116-A337-7C31A4405D56Q33741953-D47E2092-671C-418D-B810-65E93B129807Q33742804-3F34801B-ABA6-4D09-81A6-C3571D322416Q33742958-69153579-8D46-489E-B85D-728630A4C059Q33750394-2CC119FB-2AA8-4593-BD16-697A76DCB019Q33759572-91652EA5-DD9E-4D86-BCD2-5C0EA9AF416FQ33975885-1CF26BAB-EF50-4F3E-BDFF-2DC5AF4A29BEQ33976928-7016CDAF-7275-46F3-A88E-58AF84BFA869Q33977440-287EE13E-7219-4F33-A39B-88E848CC3A9EQ33979371-9A99B5B9-1F79-46B9-89A4-7BC03DDB98C2Q33980062-AA606B0C-847B-4AD2-8A9E-1B4D1607D0CDQ33981950-38162132-D8BE-45C7-9B65-7949E2B70A3AQ34044442-140FAA38-198C-4EE3-8AD4-8376420AA60EQ34077019-0FC57638-CD7D-472E-9205-149178012916Q34142971-00249B0E-FA8E-4E12-8203-78EB8A611462Q34244192-F0D28A3D-41E0-47F7-BDD5-79B4336B9288Q34252432-EE2DCF81-8E74-4837-AAE5-0A3D7F605CF0
P2860
Method of reliable determination of minimal lethal antibiotic concentrations.
description
1980 nî lūn-bûn
@nan
1980 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Method of reliable determination of minimal lethal antibiotic concentrations.
@ast
Method of reliable determination of minimal lethal antibiotic concentrations.
@en
type
label
Method of reliable determination of minimal lethal antibiotic concentrations.
@ast
Method of reliable determination of minimal lethal antibiotic concentrations.
@en
prefLabel
Method of reliable determination of minimal lethal antibiotic concentrations.
@ast
Method of reliable determination of minimal lethal antibiotic concentrations.
@en
P2093
P2860
P356
P1476
Method of reliable determination of minimal lethal antibiotic concentrations.
@en
P2093
R D Pearson
R T Steigbigel
S W Chapman
P2860
P304
P356
10.1128/AAC.18.5.699
P407
P577
1980-11-01T00:00:00Z